These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 10926177)

  • 1. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers.
    Weir MR; Henrich WL
    Curr Opin Nephrol Hypertens; 2000 Jul; 9(4):403-11. PubMed ID: 10926177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases].
    Huber K; Pachinger O; Pichler M; Klein W
    Z Kardiol; 1997 Apr; 86(4):239-50. PubMed ID: 9235795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
    Weber MA
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):189S-194S. PubMed ID: 10619571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blockers: evidence for preserving target organs.
    Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
    Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences.
    Stergiou GS; Skeva II
    Curr Top Med Chem; 2004; 4(4):473-81. PubMed ID: 14965313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
    Johnston CI
    Blood Press Suppl; 2000; 1():9-13. PubMed ID: 11059629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin inhibition--benefit beyond hypertension control.
    Kher V
    J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of angiotensin II on the kidney: does an angiotensin II receptor blocker make sense?
    Hollenberg NK
    Am J Kidney Dis; 2000 Sep; 36(3 Suppl 1):S18-23. PubMed ID: 10986155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin converting enzyme inhibition and the kidney.
    Hollenberg NK
    Curr Opin Cardiol; 1988; 3(Suppl 1):S19-29. PubMed ID: 11538849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preclinical basis of the therapeutic evaluation of losartan.
    Timmermans PB; Wong PC; Chiu AT; Smith RD
    J Hypertens Suppl; 1995 Jul; 13(1):S1-13. PubMed ID: 18800450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of renin-angiotensin to calcium channel blockade in renal disease.
    Tikkanen I; Johnston CI
    Kidney Int Suppl; 1997 Dec; 63():S19-22. PubMed ID: 9407414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the prevention of progression of renal disease.
    Ram CV; Vergne-Marini P
    Curr Hypertens Rep; 1999 Oct; 1(5):431-5. PubMed ID: 10981102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists.
    Campbell DJ
    Clin Exp Pharmacol Physiol Suppl; 1996; 3():S125-31. PubMed ID: 8993851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of ACE inhibitors versus AT1 blockers.
    Vaughan D
    Can J Cardiol; 2000 Aug; 16 Suppl E():36E-40E. PubMed ID: 10906625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-angiotensin system blocking drugs.
    Robles NR; Cerezo I; Hernandez-Gallego R
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):14-33. PubMed ID: 24038019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.